AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35180284 — intervention group
Group type: COMPARATOR
Intervention: Decrease in dietary vitamin K intake (median -97.8 μg/d)
Number of subjects: 5533
Study 35180284 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake
Number of subjects: 5533
Study 34817971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariestop (Biodinamica Quimica y Farmaceutica)
Number of subjects: 90
Study 34817971 — intervention group
Group type: EXPERIMENTAL
Intervention: RivaStar 1 (SDI)
Number of subjects: 90
Study 34817971 — intervention group
Group type: EXPERIMENTAL
Intervention: RivaStar 2 (SDI)
Number of subjects: 90
Study 34817971 — intervention group
Group type: EXPERIMENTAL
Intervention: Saforide (Tokyo Seiyaku Kasei)
Number of subjects: 90
Study 34817971 — intervention group
Group type: COMPARATOR
Intervention: Demineralized dentin (positive control)
Number of subjects: 90
Study 34817971 — intervention group
Group type: COMPARATOR
Intervention: Sound dentin (negative control)
Number of subjects: 90
Study 36087070 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509
Study 36087070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study 34397500 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic conversation with an ED nurse
Number of subjects: 166
Study 34397500 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 166
Study 32479645 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychological intervention targeting fear of recurrence
Number of subjects: 0
Study 32479645 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care implementation
Number of subjects: 0
Study 35653145 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg, twice daily) plus endocrine therapy (ET) for 2 years
Number of subjects: 5637
Study 35653145 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 5637
Study 32554173 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-version of Prolonged Exposure (Web-PE) therapy
Number of subjects: 0
Study 32554173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) delivered in-person as part of an intensive outpatient PTSD program
Number of subjects: 0
Study 32554173 — intervention group
Group type: COMPARATOR
Intervention: In-person Present-Centered Therapy (PCT)
Number of subjects: 0
Study 35910936 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM)
Number of subjects: 70
Study 34992553 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy conducted by trained music therapists
Number of subjects: 57
Study 34992553 — intervention group
Group type: COMPARATOR
Intervention: Music listening together with a social care worker
Number of subjects: 57
Study 34992553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Music therapy and Music listening)
Number of subjects: 57
Study 34992553 — intervention group
Group type: COMPARATOR
Intervention: Music therapy and Music listening
Number of subjects: 57
Study 32067251 — intervention group
Group type: EXPERIMENTAL
Intervention: Refugee Well‐being Project (RWP) intervention, a 6-month multilevel, strengths‐based program involving university students and refugees.
Number of subjects: 290
Study 36473717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavandula essential oil (LEO) - 5 drops of 20% LEO inhaled for three consecutive days, intervention performed every 24 hours.
Number of subjects: 98
Study 36473717 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 5 drops of distilled water inhaled for three consecutive days, intervention performed every 24 hours.
Number of subjects: 98
Study 33165310 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk training (N=19)
Number of subjects: 45
Study 33165310 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (N=20)
Number of subjects: 45
Study 33165310 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk training
Number of subjects: 45
Study 32042108 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning classes (07:45)
Number of subjects: 753
Study 32042108 — intervention group
Group type: COMPARATOR
Intervention: Afternoon classes (12:40)
Number of subjects: 753
Study 32042108 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening classes (17:20)
Number of subjects: 753
Study 35633027 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg bid (starting dose 500 mg) for 12 weeks
Number of subjects: 50
Study 34289514 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard conservative management plus acupuncture (6 sessions over 8 weeks)
Number of subjects: 30
Study 34289514 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative management for OAB
Number of subjects: 30
Study 34289514 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard conservative management plus acupuncture
Number of subjects: 30
Study 32711802 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued prednisone 5 mg per day for 24 weeks
Number of subjects: 259
Study 32711802 — intervention group
Group type: COMPARATOR
Intervention: Tapered prednisone reaching 0 mg per day at week 16
Number of subjects: 259
Study 32711802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 259
Study 32711802 — intervention group
Group type: COMPARATOR
Intervention: Tapered prednisone
Number of subjects: 259
Study 32711802 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued prednisone
Number of subjects: 259
Study 35667659 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-type fructan intervention
Number of subjects: 0
Study 35667659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34547064 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown lengthening and tooth reconstruction (experimental group)
Number of subjects: 126
Study 34547064 — intervention group
Group type: COMPARATOR
Intervention: Extraction and replacement (control group)
Number of subjects: 126
Study 36134818 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicitis Inflammatory Response score flowchart
Number of subjects: 110
Study 36134818 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical-radiological diagnosis
Number of subjects: 110
Study 35476136 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative exercises (treadmill running, lower extremity strengthening exercises, plyometric exercises) for 30 minutes each
Number of subjects: 12
Study 35476136 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric loading
Number of subjects: 12
Study 32298662 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP+ group (presence of MEPs)
Number of subjects: 28
Study 32298662 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP- group (absence of MEPs)
Number of subjects: 28
Study 32298662 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 28
Study 35351020 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cells (UCB-MNCs) administered via intrathecal route (5 × 10^6 /kg)
Number of subjects: 72
Study 35351020 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 72
Study 33954853 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + intervention
Number of subjects: 31
Study 33954853 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 31
Study 32621735 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert advice on therapeutic exercise
Number of subjects: 500
Study 32621735 — intervention group
Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 500
Study 36208780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate green space VR exposure
Number of subjects: 63
Study 36208780 — intervention group
Group type: EXPERIMENTAL
Intervention: High green space VR exposure
Number of subjects: 63
Study 33964099 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 54
Study 32860117 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent short bouts of physical activity (FPA)
Number of subjects: 16
Study 32860117 — intervention group
Group type: COMPARATOR
Intervention: Sitting (SIT)
Number of subjects: 16
Study 32860117 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (EXE)
Number of subjects: 16
Study 32860117 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to 5 min post-PAS
Number of subjects: 16
Study 36435926 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care program (4 sessions of 45-60 min each, one session per week)
Number of subjects: 108
Study 36435926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 108
Study 34880055 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive, standardised, nurse led telephone management of common toxicities
Number of subjects: 2158
Study 34880055 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 2158
Study 35930800 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation phase
Number of subjects: 17
Study 35930800 — intervention group
Group type: EXPERIMENTAL
Intervention: Late luteal phase
Number of subjects: 17
Study 35930800 — intervention group
Group type: COMPARATOR
Intervention: Menstruation, mid-follicular, and late luteal phases
Number of subjects: 17
Study 35115225 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpoint transverse process-to-pleura block (MTPB)
Number of subjects: 81
Study 35115225 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 81
Study 36099251 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSG) training group (n = 12)
Number of subjects: 24
Study 36099251 — intervention group
Group type: COMPARATOR
Intervention: Simulated Match Handball Training (SMHT) group (n = 12)
Number of subjects: 24
Study 34099403 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bio‐regenerative fibrin
Number of subjects: 74
Study 34099403 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods of hemostasis
Number of subjects: 74
Study 32766883 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge thrombosis (including arterial and venous events)
Number of subjects: 163
Study 32766883 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge venous thromboembolism
Number of subjects: 163
Study 32766883 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge major hemorrhage
Number of subjects: 163
Study 32766883 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge clinically relevant nonmajor bleeds
Number of subjects: 163
Study 34661691 — intervention group
Group type: EXPERIMENTAL
Intervention: CEX-p-FAST
Number of subjects: 296
Study 34661691 — intervention group
Group type: COMPARATOR
Intervention: CEX-only
Number of subjects: 296
Study 34016436 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack application for medication management
Number of subjects: 153
Study 34016436 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication management
Number of subjects: 153
Study 33361075 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dry cupping
Number of subjects: 62
Study 33361075 — intervention group
Group type: COMPARATOR
Intervention: Sham dry cupping
Number of subjects: 62
Study 35486613 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC (2.8 million ASCs/cm3 injection)
Number of subjects: 30
Study 35486613 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC
Number of subjects: 30
Study 35486613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32868497 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO modified checklist
Number of subjects: 0
Study 32868497 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO checklist
Number of subjects: 0
Study 32868497 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no checklist)
Number of subjects: 0
Study 32868497 — intervention group
Group type: EXPERIMENTAL
Intervention: All checklist groups
Number of subjects: 0
Study 35152576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding therapy with PGLA thread applied to acupoints (Tianshu, Zhongwan, Ganshu, Shuidao) once every 2 weeks for 12 weeks.
Number of subjects: 144
Study 35152576 — intervention group
Group type: COMPARATOR
Intervention: Sham-embedding group (same acupoint selection and operation without PGLA thread).
Number of subjects: 144
Study 35152576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding therapy with PGLA thread.
Number of subjects: 144
Study 33125518 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+PLGA/PLA nanoparticles loaded with 50 μg of curcumin (N‐Curc)
Number of subjects: 20
Study 33125518 — intervention group
Group type: COMPARATOR
Intervention: SRP+empty nanoparticles (Control)
Number of subjects: 20
Study 36429423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (patient messaging intervention)
Number of subjects: 420
Study 36429423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (patient messaging intervention plus online education)
Number of subjects: 420
Study 36429423 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 420
Study 34191812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin-albendazole
Number of subjects: 2050
Study 34191812 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 2050
Study 32271377 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (20 mg/kg every 4 weeks)
Number of subjects: 1118
Study 32271377 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (20 mg/kg durvalumab + 1 mg/kg tremelimumab every 4 weeks, up to 4 doses)
Number of subjects: 1118
Study 32271377 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 1118
Study 32271377 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based doublet)
Number of subjects: 1118
Study 36138361 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A based self‐management program for 6 weeks (in‐person and off‐site)
Number of subjects: 72
Study 36138361 — intervention group
Group type: COMPARATOR
Intervention: Routine care includes stroke training booklets and post‐discharge care training by the ward nurse
Number of subjects: 72
Study 35223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg; 30 minutes before bedtime) for 2 weeks
Number of subjects: 110
Study 35223393 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 110
Study 35223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg; 30 minutes before bedtime)
Number of subjects: 110
Study 34881919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 125
Study 34881919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 32770384 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) alone
Number of subjects: 87
Study 32770384 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) with estradiol add‐back
Number of subjects: 87
Study 32770384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (antioxidant) infusion
Number of subjects: 87
Study 32770384 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRHant) + placebo
Number of subjects: 87
Study 32770384 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (GnRHant) + estradiol
Number of subjects: 87
Study 35987829 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 55
Study 35987829 — intervention group
Group type: COMPARATOR
Intervention: Technical Assistance (TA)
Number of subjects: 55
Study 34148124 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation (HA) training for 5 days at 34.9 ± 0.7 °C, 53 ± 4% relative humidity
Number of subjects: 8
Study 34148124 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) training for 5 days at 22.2 ± 2.6 °C, 65 ± 8% relative humidity
Number of subjects: 8
Study 35561963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TNS
Number of subjects: 20
Study 35561963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20
Study 35561963 — intervention group
Group type: COMPARATOR
Intervention: Sham TNS
Number of subjects: 20
Study 34039938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale (GCS) score
Number of subjects: 773
Study 34039938 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented acute mental status
Number of subjects: 773
Study 34039938 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS score documentation
Number of subjects: 773
Study 36191643 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexanolone 90 μg/kg/h (BRX90)
Number of subjects: 209
Study 36191643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 33315355 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 68
Study 33315355 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin
Number of subjects: 68
Study 32025830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd-generation DSCT
Number of subjects: 575
Study 616484288 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of H1‐AHs
Number of subjects: 136
Study 616484288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd line treatments (combining or updosing AHs)
Number of subjects: 136
Study 616484288 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab as a 3rd line treatment
Number of subjects: 136
Study 616484288 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing omalizumab treatment for 24 weeks
Number of subjects: 136
Study 616484288 — intervention group
Group type: COMPARATOR
Intervention: 2nd line treatments
Number of subjects: 136
Study 34376546 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating seated-standing protocol (training group)
Number of subjects: 30
Study 34376546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alternating seated-standing protocol)
Number of subjects: 30
Study 33258890 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (13.75 mg)
Number of subjects: 26
Study 33258890 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD-equivalent cannabis (13.75 mg)
Number of subjects: 26
Study 33258890 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-dominant cannabis (13.75 mg)
Number of subjects: 26
Study 33258890 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 26
Study 37453240 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study 37453240 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) + Bevacizumab (BEV)
Number of subjects: 0
Study 34459214 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 545
Study 34459214 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 545
Study 32184198 — intervention group
Group type: EXPERIMENTAL
Intervention: Written exposure therapy
Number of subjects: 300
Study 32184198 — intervention group
Group type: COMPARATOR
Intervention: Imaginal exposure
Number of subjects: 300
Study 36054624 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 36054624 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30
Number of subjects: 0
Study 32804837 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicin-containing quadruple therapy (IDFA)
Number of subjects: 220
Study 32804837 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (IDFB)
Number of subjects: 220
Study 36172933 — intervention group
Group type: COMPARATOR
Intervention: LDL-C 70 to 100 mg/dL
Number of subjects: 8500
Study 36172933 — intervention group
Group type: COMPARATOR
Intervention: LDL-C <70 mg/dL
Number of subjects: 8500
Study 33612359 — intervention group
Group type: EXPERIMENTAL
Intervention: AP overlay with Gel pad
Number of subjects: 180
Study 33612359 — intervention group
Group type: COMPARATOR
Intervention: Gel pad
Number of subjects: 180
Study 32314781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 40
Study 32314781 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate (CEE+MPA)
Number of subjects: 40
Study 34788822 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-containing B vitamins
Number of subjects: 545
Study 34788822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 34145336 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus S‐1 (GS)
Number of subjects: 354
Study 34145336 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus cisplatin (GC)
Number of subjects: 354
Study 32135381 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Lactobacillus johnsonii)
Number of subjects: 18
Study 32135381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 34757487 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 34757487 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss ≥ 5%
Number of subjects: 1767
Study 34757487 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 1767
Study 34083576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 328
Study 34083576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% atropine
Number of subjects: 328
Study 35328926 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette (EC) smoking
Number of subjects: 12
Study 35328926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Cigarette (TC) smoking
Number of subjects: 12
Study 35328926 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study 33167952 — intervention group
Group type: COMPARATOR
Intervention: Balint groups
Number of subjects: 362
Study 33167952 — intervention group
Group type: COMPARATOR
Intervention: Narrative medicine training
Number of subjects: 362
Study 33167952 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 362